Daniel Courchesne
Director/Board Member at F3 Platform Biologics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jonathan Peskoff | M | 51 |
F3 Platform Biologics, Inc.
 F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | 6 years |
| James Miller | M | 58 |
F3 Platform Biologics, Inc.
F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | 6 years |
| Holger Liepmann | M | 72 |
F3 Platform Biologics, Inc.
F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | - |
| Bernardus MacHielse | M | 63 |
F3 Platform Biologics, Inc.
F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | - |
| Kevin Rooney | M | 58 |
F3 Platform Biologics, Inc.
F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | 2 years |
| Jean-François Leduc | M | - |
University of Sherbrooke
| 40 years |
| Linda Peters | F | - |
F3 Platform Biologics, Inc.
F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Luc Tanguay | M | 65 |
University of Sherbrooke
| 5 years |
| Martin Delage | M | - |
University of Sherbrooke
| 6 years |
| Serge Chiasson | M | - |
University of Sherbrooke
| 2 years |
| Guylaine Lehoux | F | - |
University of Sherbrooke
| 4 years |
| Cyrille Vittecoq | M | - |
University of Sherbrooke
| 4 years |
| P. Mario Charpentier | M | - |
University of Sherbrooke
| 4 years |
| Yvan Ouellet | M | - |
University of Sherbrooke
| 4 years |
| Jocelyn Lepine | M | - |
University of Sherbrooke
| 4 years |
| André Lachance | M | - |
University of Sherbrooke
| 4 years |
| Charles Litalien | M | - |
University of Sherbrooke
| 4 years |
| François Desjardins | M | 61 |
University of Sherbrooke
| 3 years |
| Jean-François Benoit Tardif | M | - |
University of Sherbrooke
| 4 years |
| Patrick Cabana | M | - |
University of Sherbrooke
| 4 years |
| Christian Lambert | M | 57 |
University of Sherbrooke
| 4 years |
| Serge Dussault | M | - |
University of Sherbrooke
| 4 years |
| Pierre Bonin | M | 60 |
University of Sherbrooke
| 4 years |
| François Dufresne | M | 63 |
University of Sherbrooke
| 1 years |
| Luc Paquet | M | 59 |
University of Sherbrooke
| 4 years |
| Bernard Guy | M | 59 |
University of Sherbrooke
| 4 years |
| Vanessa Laplante | F | - |
University of Sherbrooke
| 4 years |
| Diane Fontaine | F | 60 |
University of Sherbrooke
| 4 years |
| Robert A. Dubé | M | - |
University of Sherbrooke
| 3 years |
| René Bousquet | M | - |
University of Sherbrooke
| 5 years |
| Eric Reiher | M | - |
University of Sherbrooke
| 4 years |
| Robert Hall | M | 67 |
University of Sherbrooke
| 3 years |
| Luc Houle | M | 67 |
University of Sherbrooke
| 4 years |
| Carl Simard | M | - |
University of Sherbrooke
| 2 years |
| Louis Philippe Chasles | M | - |
University of Sherbrooke
| 3 years |
| Rémi Roger | M | - |
University of Sherbrooke
| 4 years |
| Benoit Chotard | M | 59 |
University of Sherbrooke
| 4 years |
| André Bolduc | M | - |
University of Sherbrooke
| 4 years |
| Benoît Gauvin | M | - |
University of Sherbrooke
| 4 years |
| Charles Spector | M | 65 |
University of Sherbrooke
| 3 years |
| André Lepage | M | - |
University of Sherbrooke
| 3 years |
| Yvan Fontaine | M | - |
University of Sherbrooke
| 1 years |
| Michel Letellier | M | 59 |
University of Sherbrooke
| 2 years |
| André Michel | M | - |
University of Sherbrooke
| 10 years |
| Pierre Fréchette | M | - |
University of Sherbrooke
| 4 years |
| Alain Bellemare | M | 63 |
University of Sherbrooke
| 4 years |
| Joe DiMassimo | M | - |
University of Sherbrooke
| 2 years |
| René Caron | M | - |
University of Sherbrooke
| 4 years |
| M. Jacques Joly | M | - |
University of Sherbrooke
| 4 years |
| Michael Quigley | M | - |
University of Sherbrooke
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 44 | 88.00% |
| United States | 6 | 12.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Daniel Courchesne
- Personal Network
